S SEAMLESS
Live / Allowed — Published for opposition (as of 17 Mar 2026)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 14 Dec 2023 filing date already counts against anyone who files later.
Record
- Serial number
- 79408326
- Mark type
- Design + words
- Filed
- 14 Dec 2023
- Published for opposition
- 17 Mar 2026
- Attorney of record
- Brian J. Focarino
Goods and services
- Class 001 — Chemicals: Chemicals for use in industry and science; biological preparations for use in industry and science, biological reagents, for use in industry and science, not for medical purposes
- Class 005 — Pharmaceuticals: Pharmaceutical and biological preparations for gene therapies and gene-editing therapies, all for the treatment of genetic and viral diseases; medical, pharmaceutical and biopharmaceutical preparations and substances containing programmable recombinases for the treatment of genetic and viral diseases; pharmaceutical goods and preparations, namely, gene transfer, regulation, modulation and delivery medications for the treatment of genetic and viral diseases and disorders; products, agents, for medical purposes, for veterinary purposes in the nature of pharmaceutical preparations for cellular, genome and gene editing therapies to treat genetic, oncological, immune system-related, and inflammatory disorders and diseases; genome editable enzymes being enzymes for medical purposes; DNA recombinant enzymes being enzymes for medical purposes; DNA editable enzymes, especially, recombinases and integrases being enzymes for medical purposes; genome editable enzymes for the treatment of diseases being enzymes for medical purposes; DNA recombinant enzymes for the treatment of diseases being enzymes for medical purposes; DNA editable enzymes, in particular recombinases and integrases, for the treatment of diseases being enzymes for medical purposes
- Class 042 — Scientific and technological services: Scientific and technological services, namely, product research and testing of pharmaceuticals for cell and gene therapies in the field of pharmaceutical product development for the creation of bioinformatic algorithms and models; development of pharmaceutical preparations and medicines, none of the foregoing for diagnostics; pharmaceutical product development, none of the foregoing for diagnostics; pharmaceutical products development of genome editable enzymes for treatment and not diagnostic purposes; pharmaceutical products development of DNA editable enzymes, in particular recombinases and integrases, for treatment and not diagnostic purposes
Owner
Prosecution history
- 30 Mar 2026 — NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
- 29 Mar 2026 — NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
- 19 Mar 2026 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 19 Mar 2026 — TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
- 19 Mar 2026 — ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
- 19 Mar 2026 — TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
- 17 Mar 2026 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 17 Mar 2026 — PUBLISHED FOR OPPOSITION
- 12 Mar 2026 — NOTIFICATION PROCESSED BY IB
- 11 Mar 2026 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 25 Feb 2026 — NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
- 24 Feb 2026 — NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
- 18 Feb 2026 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 18 Feb 2026 — EXAMINER'S AMENDMENT ENTERED
- 18 Feb 2026 — NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED